{'fraction_non_alphanumeric': 0.022908366533864542, 'fraction_numerical': 0.0, 'mean_word_length': 5.568627450980392, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Presence of the elastin-laminin receptor on human activated lymphocytes.

A variety of cells - fibroblasts, vascular smooth muscle cells, endothelial cells, monocytes and polymorphonuclear leukocytes (PMNs) - carry the elastin-laminin receptor. The activation of this receptor by elastin peptides triggers a variety of reactions as chemotactic movements to an elastin peptide gradient, release of lytic enzymes and oxygen-free radicals, modifications of ion fluxes. We now show that human lymphocytes also express this receptor. Membrane labelling of the receptor by specific antibodies shows capping. In the presence of elastin peptides lymphocytes show increased proliferation and increased production of an elastase type serine protease apparently identical to PMN-elastase, inhibited by cycloheximide and by anti-PMN elastase antibodies. T-lymphocytes are present in atherosclerotic plaques where elastin degradation occurs and could contribute to the chronicity of the lesion by the above mechanism.